Stryker Q2 - Ahead of expectations

Last week, Stryker delivered market-beating numbers. This medical device company has been a Vestact-recommended stock since January 2014. Revenue came in at $6 billion, up 11.1% year on year and earnings per share was $3.13, up 11.4%. Forward guidance was boosted higher, demonstrating positive momentum of the business, which is encouraging.

The management team mentioned that new tariffs are expected to cost the company $175 million this year. A small amount in the grand scheme of things, but still money that could have been added to shareholder pockets.

We have 852 clients who hold Stryker shares, but out of all our stocks it is probably the least talked about by customers. That's not a bad thing, as it steadily ticks higher, consistently delivering double-digit growth. The overall return in the last five years is 99%, which is excellent.

Onwards and upwards.